Extended Data Fig. 1: PF-05221304 efficacy in patients with NAFLD. | Nature Medicine

Extended Data Fig. 1: PF-05221304 efficacy in patients with NAFLD.

From: ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Extended Data Fig. 1

MMRM analysis of percent change from baseline over time in a, CAP in the overall population (Placebo n = 55, PF-05221304 2 mg, n = 56, 10 mg n = 62, 25 mg n = 52, 50 mg n = 53) and, b, VCTE in the NASH subgroup (Placebo n = 42, PF-05221304 2 mg, n = 43, 10 mg n = 42, 25 mg n = 39, 50 mg n = 42), using FibroScan®, and in c, T-bili (Placebo n = 40, PF-05221304 2 mg, n = 42, 10 mg n = 42, 25 mg n = 39, 50 mg n = 40), and d–g, procollagen isoforms in the NASH subgroup (Placebo n = 39, PF-05221304 2 mg, n = 40, 10 mg n = 42, 25 mg n = 35, 50 mg n = 38), and h, HbA1c in patients with T2D (Placebo n = 23, PF-05221304 2 mg, n = 23, 10 mg n = 26, 25 mg n = 25, 50 mg n = 23). i, Percent change from baseline to last observation in liver fat (MRI–PDFF) versus fasting serum triglyceridesa and j, percent change from baseline in fasting serum triglycerides versus baseline fasting serum triglyceridesa. MMRM analysis of percent change from baseline over time to week 16 in the overall population in k, total cholesterol (Placebo n = 58, PF-05221304 2 mg, n = 62, 10 mg n = 62, 25 mg n = 58, 50 mg n = 59), and l, Apo E (Placebo n = 57, PF-05221304 2 mg, n = 60, 10 mg n = 62, 25 mg n = 54, 50 mg n = 56). Data in panels a–h and k–l represent LSM (80% CI) from an MMRM model. aOne patient in the PF-05221304 10 mg treatment group with a percent change from baseline to last observation in fasting serum triglycerides of 1727.9 was excluded from these graphs for visualization but was included in the analysis. This patient had a percent change in liver fat of –38.9 and fasting serum triglycerides at baseline were 104 mg/dL (1.17 mmol/L). Apo, apolipoprotein; CAP, controlled attenuation parameter; CI, confidence interval; HbA1c, glycated hemoglobin; LSM, least squares mean; MMRM, mixed-effects model for repeated measures; MRI–PDFF, magnetic resonance imaging-proton density fat fraction; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PF’1304, PF-05221304; Pro-C, procollagen type; T-bili, total bilirubin; T2D, type 2 diabetes; VCTE, vibration-controlled transient elastography.

Source data

Back to article page